Opinion on Pharmaceuticals and Healthcare in Germany

Published within

« | ... | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | ... | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Cancer: breast tumors most prevalent in 2001

Published By Datamonitor
22 Aug 2002
ResearchWire
ResearchWire

Malignant melanoma: incidence to hit 77,000 in 2010

Published By Datamonitor
28 Aug 2002
ResearchWire
ResearchWire

Knee arthroplasty: 90% of bearings used in Germany are mobile

Published By Datamonitor
03 Sep 2002
CommentWire
CommentWire

Bayer: seeking Gamunex approval

Bayer has filed for approval for its immune globulin intravenous drug, Gamunex. It's a purer alternative to Bayer's existing Gamimune; its major indication is primary immunodeficiency. For Gamunex to be a major success, Bayer will need to convince healthcare payors that its lower risk of associated infection makes it more cost-effective than its stablemate.

Published By Datamonitor
10 Sep 2002
ResearchWire
ResearchWire

Ovarian cancer: incidence to hit 58,000 in 2010

Published By Datamonitor
19 Sep 2002
ResearchWire
ResearchWire

Breast cancer: 463,000 new cases predicted in 2010

Published By Datamonitor
30 Sep 2002
CommentWire
CommentWire

Novo Nordisk: long-acting insulin to take on Aventis

Novo Nordisk's new insulin analog NN304 should launch in Europe next year, as long as it gains regulatory approval. This will bring it into direct competition with Aventis' Lantus. While that drug has first-to-market advantage, Aventis has yet to market it to the all of the major European markets. The fight for other European markets will be fierce.

Published By Datamonitor
07 Nov 2002
CommentWire
CommentWire

Cialis: standing ovation for new launch

The launch of Viagra, the world's first treatment for impotency and erectile dysfunction, was an instant success. Now, Lilly ICOS has officially launched Cialis, Viagra's first direct competition, and there is more on the way. In a growing market, Cialis' advantages over Viagra mean that it could reach blockbuster status.

Published By Datamonitor
05 Feb 2003
CommentWire
CommentWire

GSK: antidepressant leader under threat

The Chicago court ruling will see Apotex's Paxil generic impact the GSK bi-blockbuster antidepressant from 2005. Moreover, GSK's follow up antidepressant, vilazadone, appears to be struggling to proceed to market, leaving GSK with a wealth of depression expertise but a foreseeable dent in its antidepressant revenue stream.

Published By Datamonitor
07 Mar 2003
CommentWire
CommentWire

AstraZeneca: Crestor experiences additional setbacks

Withdrawal from the European approval process by three member states represents additional obstacles for Crestor, heightens concerns over safety, and will undoubtedly slow revenue gains for AstraZeneca. Therefore, although forecast to achieve blockbuster sales of $3.8 billion in 2010, Crestor will fail to make as significant an impact on the anti-dyslipidemic market as Lipitor did upon launch.

Published By Datamonitor
12 Mar 2003

« | ... | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | ... | » »|

No help is available.